The Effect of Biologics in the Treatment of Multisystem Inflammatory Syndrome in Children (Mis-C): A Single-Center Propensity-Score-Matched Study

• Published in: Children (Basel) Vol. 10; no. 6; p. 1045
• Main Authors: Basaran, Ozge, Batu, Ezgi Deniz, Kaya Akca, Ummusen, Atalay, Erdal, Kasap Cuceoglu, Muserref, Sener, Seher, Balık, Zeynep, Karabulut, Erdem, Kesici, Selman, Karagoz, Tevfik, Ozsurekci, Yasemin, Bilginer, Yelda, Cengiz, Ali Bulent, Ozen, Seza
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.06.2023; MDPI
• Subjects: biologic; Biological products; Care and treatment; children; comparison; Coronaviruses; COVID-19; Cytokines; Drug dosages; Ejection fraction; Fever; Inflammation; Intensive care; management; Medical laboratories; Multisystem inflammatory syndrome in children; multisystem inflammatory syndrome in children (MIS-C); Normal distribution; outcomes; Patients; Pediatrics; Steroids; Variables; Variance analysis; comparison; multisystem inflammatory syndrome in children (MIS-C); children; management; outcomes; biologic
• ISSN: 2227-9067; 2227-9067
• DOI: 10.3390/children10061045

Multisystem inflammatory syndrome in children (MIS-C) is a serious condition characterized by excessive inflammation that can arise as a complication of SARS-CoV-2 infection in children. While our understanding of COVID-19 and MIS-C has been advancing, there is still uncertainty regarding the optimal treatment for MIS-C. In this study, we aimed to compare the clinical and laboratory outcomes of MIS-C patients treated with IVIG plus corticosteroids (CS) to those treated with IVIG plus CS and an additional biologic drug. We used the propensity score (PS)-matching method to assess the relationships between initial treatment and outcomes. The primary outcome was a left ventricular ejection fraction of less than 55% on day 2 or beyond and/or the requirement of inotrope support on day 2 or beyond. We included 79 MIS-C patients (median age 8.51 years, 33 boys) followed in our center. Among them, 50 children (25 in each group) were allocated to the PS-matched cohort sample. The primary outcome was observed in none of the patients in the IVIG and CS group, while it occurred in eight patients in the IVIG plus CS and biologic group ( = 0.04). MIS-C is a disorder that may progress rapidly and calls for extensive care. For definitive recommendations, further studies, including randomized control trials, are required.